Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Revenue (2020 - 2025)

Historic Revenue for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $10.0 million.

  • Janux Therapeutics' Revenue rose 217790.43% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year decrease of 2336.58%. This contributed to the annual value of $10.6 million for FY2024, which is 3099.1% up from last year.
  • As of Q3 2025, Janux Therapeutics' Revenue stood at $10.0 million, which was up 217790.43% from $439000.0 recorded in Q3 2024.
  • In the past 5 years, Janux Therapeutics' Revenue registered a high of $10.0 million during Q3 2025, and its lowest value of $380000.0 during Q1 2021.
  • In the last 5 years, Janux Therapeutics' Revenue had a median value of $1.7 million in 2021 and averaged $2.6 million.
  • As far as peak fluctuations go, Janux Therapeutics' Revenue plummeted by 8255.86% in 2024, and later soared by 217790.43% in 2025.
  • Over the past 5 years, Janux Therapeutics' Revenue (Quarter) stood at $1.6 million in 2021, then surged by 76.05% to $2.8 million in 2022, then decreased by 13.5% to $2.5 million in 2023, then tumbled by 82.16% to $439000.0 in 2024, then soared by 2177.9% to $10.0 million in 2025.
  • Its Revenue was $10.0 million in Q3 2025, compared to $439000.0 in Q3 2024 and $8.9 million in Q2 2024.